1/1
4 files

RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial

dataset
posted on 15.01.2021, 09:05 by Thomas Scriba, Andrew Fiore-Gartland, Adam Penn-Nicholson, Humphrey Mulenga, Stanley Kimbung, Bhavesh Borate, Simon Mendelsohn, Katie Hadley, Chris Hikuam, Masooda Kaskar, Munyaradzi Musvosvi, Nicole Bilek, Steven Self, Tom Sumner, Richard White, Mzwandile Erasmus, Lungisa Jaxa, Rodney Raphela, Craig Innes, William Brumskine, Andriëtte Hiemstra, Stephanus T. Malherbe, Razia Hassan-Moosa, Michèle Tameris, Gerhard Walzl, Kogieleum Naidoo, Gavin Churchyard, Mark Hatherill
RISK11 transcriptomic signature scores for 20,207 volunteers who were screened at five geographically diverse sites across South Africa. Signature scores were computed from QC'ed gene expression measurements performed by microfluidic RT-qPCR on mRNA derived from whole blood collected in PAXgene tubes. Participants were randomised into three groups and followed-up for 15 months to evaluate diagnostic and prognostic performance of RISK11 and to evaluate efficacy of high-dose isoniazid and rifapentine for prevention of incident TB.

Funding

Bill & Melinda Gates Foundation (OPP1116632, OPP1137034)

Strategic Health Innovation Partnerships Unit of the South African Medical Research Council

History

Department/Unit

Department of Pathology

Licence

Exports

South African Tuberculosis Vaccine Initiative (SATVI)

Licence

Exports